AB Science S.A - Asset Resilience Ratio
AB Science S.A (AB) has an Asset Resilience Ratio of 0.00% as of June 2025. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio Trend (2009–2024)
This chart shows how AB Science S.A's Asset Resilience Ratio has changed over time. Check AB capital-intensive asset ratio to assess the company's strategic physical and investment asset allocation.
Liquid Assets Composition Over Time
This chart breaks down AB Science S.A's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For market capitalisation and broader financial context, see AB Science S.A market capitalisation.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €1.00K | 0.0% |
| Short-term Investments | €0.00 | 0% |
| Total Liquid Assets | €1.00K | 0.00% |
Asset Resilience Insights
- Limited Liquidity: AB Science S.A maintains only 0.00% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company primarily holds liquidity in cash and equivalents rather than short-term investments.
AB Science S.A Industry Peers by Asset Resilience Ratio
Compare AB Science S.A's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Shanghai Haoyuan Chemexpress Co. Ltd. A
SHG:688131 |
Drug Manufacturers - Specialty & Generic | 1.37% |
|
Beijing New Oriental Star Petrochemical Engineering Co Ltd
SHE:002755 |
Drug Manufacturers - Specialty & Generic | 24.59% |
|
Zhejiang Hisoar Pharmaceutical Co Ltd
SHE:002099 |
Drug Manufacturers - Specialty & Generic | 0.20% |
|
Celltrion Pharm Inc
KQ:068760 |
Drug Manufacturers - Specialty & Generic | 12.49% |
|
Shanghai Yizhong Pharmaceutical Co Ltd
SHG:688091 |
Drug Manufacturers - Specialty & Generic | 26.36% |
|
Heilongjiang ZBD Pharmaceutical Co Ltd
SHG:603567 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Zhejiang Anglikang Pharmaceutical Co Ltd Class A
SHE:002940 |
Drug Manufacturers - Specialty & Generic | 9.11% |
Annual Asset Resilience Ratio for AB Science S.A (2009–2024)
The table below shows the annual Asset Resilience Ratio data for AB Science S.A.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2024-12-31 | 0.00% | €0.00 ≈ $0.00 |
€23.18 Million ≈ $27.09 Million |
-- |
| 2022-12-31 | 0.00% | €0.00 ≈ $0.00 |
€23.84 Million ≈ $27.87 Million |
-- |
| 2021-12-31 | 0.00% | €0.00 ≈ $0.00 |
€21.27 Million ≈ $24.87 Million |
-- |
| 2020-12-31 | 0.00% | €0.00 ≈ $0.00 |
€29.69 Million ≈ $34.71 Million |
-- |
| 2019-12-31 | 0.00% | €0.00 ≈ $0.00 |
€17.74 Million ≈ $20.74 Million |
-- |
| 2018-12-31 | 26.68% | €6.00 Million ≈ $7.02 Million |
€22.49 Million ≈ $26.29 Million |
+6.92pp |
| 2017-12-31 | 19.76% | €10.00 Million ≈ $11.69 Million |
€50.60 Million ≈ $59.16 Million |
+19.77pp |
| 2016-12-31 | 0.00% | €-1.00K ≈ $-1.17K |
€38.01 Million ≈ $44.44 Million |
-18.44pp |
| 2015-12-31 | 18.44% | €6.01 Million ≈ $7.02 Million |
€32.58 Million ≈ $38.09 Million |
-0.62pp |
| 2014-12-31 | 19.06% | €5.96 Million ≈ $6.97 Million |
€31.28 Million ≈ $36.56 Million |
+8.73pp |
| 2013-12-31 | 10.32% | €4.50 Million ≈ $5.27 Million |
€43.63 Million ≈ $51.01 Million |
-28.72pp |
| 2012-12-31 | 39.04% | €11.71 Million ≈ $13.69 Million |
€29.98 Million ≈ $35.05 Million |
+10.00pp |
| 2011-12-31 | 29.05% | €8.56 Million ≈ $10.01 Million |
€29.46 Million ≈ $34.44 Million |
-29.47pp |
| 2010-12-31 | 58.52% | €17.20 Million ≈ $20.11 Million |
€29.40 Million ≈ $34.37 Million |
+33.63pp |
| 2009-12-31 | 24.89% | €3.51 Million ≈ $4.10 Million |
€14.09 Million ≈ $16.47 Million |
-- |
About AB Science S.A
AB Science S.A., a clinical-stage company, engages in the research, design, development, and marketing of drugs to address pathologies affecting the peripheral and central nervous system, inflammatory diseases, and cancers in France. The company's lead drug candidate is masitinib, a selective protein kinase inhibitor that targets mast cells and microglia in Phase 3 trial for the treatment of amyo… Read more